They demonstrate that AZD7648 enhances the efficacy of both ionising radiation, doxorubicin and in combination with olaparib, a PARP inhibitor currently approved for breast and ovarian cancers [62]. The gene discussed is PARP1; the disease is ovarian carcinoma.